Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Safety, Tolerability and "Proof of Concept" Study of Radiotherapy, Cetuximab, and Intratumoral Injections of TNFerade™ Biologic (AdGVEGR.TNF.11D) for Elderly or Frail Patients or Intermediate Stage Patients With Head and Neck Cancer

NCT00496236 is registered in ClinicalTrials.gov with GenVec as lead sponsor.

NCT NCT00496236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00496236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Safety, Tolerability and "Proof of Concept" Study of Radiotherapy, Cetuximab, and Intratumoral Injections of TNFerade™ Biologic (AdGVEGR.TNF.11D) for Elderly or Frail Patients or Intermediate Stage Patients With Head and Neck Cancer
Lead sponsor
GenVec
Phase
Phase 1/2
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck neoplasms